Morgan Stanley raises Biogen (NASDAQ:BIIB) price target from $363 to $381

By / / Biogen, Morgan Stanley

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $363 to $381.

Scroll to Top